CoChat

Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Bortezomib represents the first proteasome inhibitor (PI) with demonstrated antitumor activity in the clinical setting, particularly for treatment of hematological malignancies. At the preclinical level, its action is shown to be mediated by induction of growth arrest and apoptosis in many tumor types, including androgen-dependent (AD) and androgen-independent (AI) prostate cancer (PCa) cells. Hypoxia-inducible factor-1α (HIF-1α), which is directly involved in tumor growth, is one of the most studied and promising molecular targets for anti-cancer therapy and is often overexpressed in PCa. Bortezomib has been reported to impair tumor growth by also inhibiting HIF-1α. In this study, we investigated the effect of bortezomib on the expression, activity and localization of HIF-1α in LNCaP (AD) and PC3 (AI) PCa cells. First, we show that hypoxic upregulation of HIF-1α protein levels and activity involves both the PI3K/Akt/mTOR and p44/42 MAPK pathways. Second, bortezomib inhibits expression of HIF-1α protein under both normoxic and hypoxic conditions, represses HIF-1 transcriptional activity and attenuates the release of vascular endothelial growth factor. These effects correlate with the ability of bortezomib to cause dephosphorylation of phospho-Akt, phospho-p70S6K, and phospho-S6RP, thus inactivating a pathway known to be required for HIF-1α protein expression at the translational level. Furthermore, bortezomib also abrogates p44/42 MAPK phosphorylation, which results to reduce…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00109-011-0805-8

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 35 references

Cited by

See all 144

Metadata

Authors
Befani, C. D., Vlachostergios, P. J., Hatzidaki, E., Patrikidou, A., Bonanou, S., Simos, G., Papandreou, C. N., & Liakos, P.
Affiliations
University of Thessaly (GR)
Corresponding author
  • Papandreou, Christos N.
  • Liakos, Panagiotis
Venue
Journal of Molecular Medicine
Published
2011-09-10
Volume
90
Issue
1
Pages
45-54
ISSN
  • 0946-2716 (ISSN-L)
  • 1432-1440
OpenAlex
W2036941876
Cited by
135
References
35
Citations by year
2026: 4 · 2025: 5 · 2024: 4 · 2023: 11 · 2022: 11 · 2021: 18 · 2020: 6 · 2019: 11 · 2018: 2 · 2017: 8 · 2016: 12 · 2015: 16 · 2014: 7 · 2013: 14 · 2012: 6
FWCI
2.94
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Molecular Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • University of Thessaly Institutional Repository (University of Thessaly) (submittedVersion)
Funders
  • University of Thessaly
  • Janssen Pharmaceuticals
  • Cilag
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
bortezomib, HIF-1α, prostate cancer, PI3K/AKT/mTOR pathway, MAPK signaling, proteasome inhibitors, hypoxia, nuclear translocation, vascular endothelial growth factor, Akt dephosphorylation, p70S6K, castration-resistant prostate cancer, androgen-dependent prostate cancer, LNCaP cells, PC-3 cells
MeSH terms
Bortezomib, Phosphoinositide-3 Kinase Inhibitors, Hypoxia, Antineoplastic Agents, Boronic Acids, Cell Nucleus, Humans, Male, Prostatic Neoplasms, Pyrazines, Transcription, Genetic, Signal Transduction, Gene Expression Regulation, Neoplastic, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Hypoxia-Inducible Factor 1, alpha Subunit, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. https://app.cochat.ai/papers/10.1007/s00109-011-0805-8
The paper
Befani, C. D., Vlachostergios, P. J., Hatzidaki, E., Patrikidou, A., Bonanou, S., Simos, G., Papandreou, C. N., & Liakos, P. (2012). Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-011-0805-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.